Investigation of role for oxidant stress in vascular tolerance development to glyceryl trinitrate in vitro

被引:19
作者
Laight, DW
Carrier, MJ
Anggard, EE
机构
[1] William Harvey Research Institute, London, EC1M 6BQ, Charterhouse Square
关键词
nitrate tolerance; nitric oxide; reactive oxygen species; rat aorta;
D O I
10.1038/sj.bjp.0701078
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The role of reactive oxygen species (ROS) during the development of vascular cellular tolerance to glyceryl trinitrate (GTN), was studied in the rat isolated aorta. 2 Nitrate tolerance induced by a 30 min incubation with GTN (30 or 100 mu M) in vitro, was not affected by pretreatment with the intracellular superoxide anion scavenger, tiron (10 mM), or the intracellular scavenger of peroxynitrite anion and hydroxyl radical, dimethylsulphoxide (DMSO, 0.2% v v(-1)). In contrast, pretreatment with the intracellular sulphydryl donor, N-acetyl-L-cysteine (NAC, 1 mM), significantly attenuated GTN-induced tolerance. 3 Pretreatment with a putative inhibitor of oxidant stress-mediated, transcription factor NF-kappa B activation, pyrrolidine dithiocarbamate (PDTC, 50 mu M), an inhibitor of gene activation by NF-kappa B, dexamethasone (1 mu M) or an inhibitor of protein synthesis, cycloheximide (10 mu M), failed to affect tolerance development to GTN. 4 Pretreatment with DMSO (0.2% v v(-1)) or PDTC (50 mu M) depressed non-tolerant vasorelaxation to GTN (1 nM-1 mu M) per se. 5 Tiron (10 mM) abolished the reduction of ferricytochrome c by a superoxide anion generating system, assessed photometrically in vitro. In contrast, DMSO (0.2% v v(-1)), NAC (1 mM) and PDTC (50 mu M) were without effect. 6 Our data suggests that neither oxidant stress nor nuclear activation, is important in the development of cellular tolerance to GTN in rat isolated aortic smooth muscle.
引用
收藏
页码:1477 / 1482
页数:6
相关论文
共 70 条
[1]   N-ACETYLCYSTEINE DOES NOT MODIFY NITROGLYCERIN-INDUCED TOLERANCE IN CANINE VASCULAR RINGS [J].
ABDOLLAH, A ;
MOFFAT, JA ;
ARMSTRONG, PW .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1987, 9 (04) :445-450
[2]  
AHLNER J, 1991, PHARMACOL REV, V43, P351
[3]   RATIONALE FOR INTERMITTENT NITRATE THERAPY [J].
AMSTERDAM, EA .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (17) :G55-G60
[4]  
AXELSSON KL, 1982, ACTA PHARMACOL TOX, V50, P350
[5]  
BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
[6]   NITRATES IN DIFFERENT VASCULAR BEDS, NITRATE TOLERANCE, AND INTERACTIONS WITH ENDOTHELIAL FUNCTION [J].
BASSENGE, E ;
ZANZINGER, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (08) :B23-B29
[7]  
BASSENGE E, 1995, BIOL NITRIC OXIDE 5, P198
[8]  
BASSENGE E, 1995, BIOL NITRIC OXIDE 5, P193
[9]   BIOTRANSFORMATION OF ORGANIC NITRATES AND VASCULAR SMOOTH-MUSCLE CELL-FUNCTION [J].
BENNETT, BM ;
MCDONALD, BJ ;
NIGAM, R ;
SIMON, WC .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :245-249
[10]   BIOCHEMISTRY OF REDUCTION OF NITRO HETEROCYCLES [J].
BIAGLOW, JE ;
VARNES, ME ;
ROIZENTOWLE, L ;
CLARK, EP ;
EPP, ER ;
ASTOR, MB ;
HALL, EJ .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (01) :77-90